The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Trump has so far not targeted any of Biden's signature healthcare policies, including Medicare drug pricing negotiation ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

In his March 2023 budget, the then UK Chancellor, Jeremy Hunt, accordingly announced that from 2024 the Medicines and ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Datapharm operates the electronic medicines compendium (emc), a trusted online resource for HCPs and patients, which attracts ...

The recent wave of AI innovation has fallen short of transforming commercial life sciences. In 2025, European biopharmas that ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

"That's a big one," said Trump, as he was handed the WHO order to sign among dozens of others, in a signal of his ...

In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...